Sales of Nexavar, which has dominated the primary treatment market for liver cancer for 10 years, are falling. This is because prices have fallen due to the release of generic products, and the status of the first treatment for liver cancer as a new drug has been shaken. Compared to two years ago, quarterly sales have halved.

◆Tecentriq with Lenvima 1Q Sales Half

According to IQVIA, a pharmaceutical research agency, on the 30th, Lenvima recorded 2 billion won in sales in the first quarter. The figure is down 41.2% from 3.4 billion won a year earlier.

Nexavar's sales have been falling for seven consecutive quarters since the second quarter of 2020. Compared to two years